The CARF-accredited facility introduces a dedicated track for executives, founders, and high-profile individuals seeking clinical treatment with complete confidentiality and zero disruption to ...

ADT’s latest earnings call painted a cautiously optimistic picture, as strong 2025 results and robust cash generation contrasted with a deliberately muted outlook for 2026. Management stressed that ...

Shareholders of ADT would probably like to forget the past six months even happened. The stock dropped 24.4% and now trades at $6.69. This may have investors wondering how to approach the situation.

ADT, one of the UK’s most established and trusted home security providers, is proud to announce a new partnership with Arsenal, becoming the club’s Official Community Security Partner. The multi-year ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. ADT (NYSE:ADT) has acquired Origin AI, a company focused on AI-enabled Wi Fi and presence ...

The company will use Origin Wireless’ AI sensing to expand the capabilities of its smart home security products. The company will use Origin Wireless’ AI sensing to expand the capabilities of its ...

Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

ADT is a defensive, cash-generative business trading below intrinsic value, assuming it increases its ROIC. State Farm and Apollo, holding ~27% combined, may sell shares, potentially pressuring ADT’s ...

In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...

Androgen deprivation therapy (ADT), also called hormone therapy, is a common treatment for metastatic prostate cancer. It works by starving the cancer of testosterone, which fuels the tumor’s growth.